Tony Tramontin is joining Axcella to become the Cambridge, MA, biotech’s chief scienfitic officer and senior vice president of research and development. Tramontin comes to Axcella from the McKinsey & Company, where he was a partner in the consulting companys global healthcare practice. Before McKinsey, he was an experimental neuroscientists at The Rockefeller University and the University of California San Francisco.
Axcella is developing amino acid-based drugs for a wide range of diseases. Originally called Pronutria and focused on medical foods, dietary supplements, and therapeutics, the company changed its name last year to Axcella and announced it would focus on amino acid drugs.
